Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

Milademetan (DS‐3032, RAIN‐32) is an orally available mouse double minute 2 (MDM2) antagonist with potential antineoplastic activity owing to increase in p53 activity through interruption of the MDM2‐p53 interaction. This phase I, dose‐escalating study assessed the safety, tolerability, efficacy, an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer science 2021-06, Vol.112 (6), p.2361-2370
Hauptverfasser:	Takahashi, Shunji, Fujiwara, Yutaka, Nakano, Kenji, Shimizu, Toshio, Tomomatsu, Junichi, Koyama, Takafumi, Ogura, Mariko, Tachibana, Masaya, Kakurai, Yasuyuki, Yamashita, Tomonari, Sakajiri, Sakura, Yamamoto, Noboru
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Anemia Antitumor activity Appetite loss Blood cell count Blood transfusions Cancer therapies Cell cycle Cytokines Dictionaries Disease control Dosage DS‐3032 Laboratories Lymphoma Lymphomas MDM2 protein milademetan Mutation Nausea Neutropenia Oncology Original Patients Pharmacokinetics phase I clinical trial Platelets RAIN‐32 Response rates Safety Safety and security measures Solid tumors Thrombocytopenia Tumor proteins Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!